» Articles » PMID: 10362794

Acceleration of C-myc-induced Hepatocarcinogenesis by Co-expression of Transforming Growth Factor (TGF)-alpha in Transgenic Mice is Associated with TGF-beta1 Signaling Disruption

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1999 Jun 11
PMID 10362794
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously shown in transgenic mice that transforming growth factor (TGF)-alpha dramatically enhances c-myc-induced hepatocarcinogenesis by promoting proliferation and survival of hepatocellular carcinoma (HCC) cells. As transgenic livers display increased levels of mature TGF-beta1 from the early stages of hepatocarcinogenesis, we have now assessed whether impairment of TGF-beta1 signaling contributes to the deregulation of cell cycle progression and apoptosis observed during this process. Focal preneoplastic lesions lacking expression of TGF-beta receptor type II (TbetaRII) were detected in c-myc/TGF-alpha but not in c-myc livers. In c-myc/TGF-alpha mice, 40% (2/5) of adenomas and 90% (27/30) of HCCs showed down-regulation of TbetaRII expression in comparison with 11% (2/18) of adenomas and 47% (14/30) of HCCs in c-myc mice. Down-regulation of the TGF-beta1-inducible p15(INK4B) mRNA and reduced apoptotic rates in TbetaRII-negative HCCs further indicated the disruption of TGF-beta1 signaling. Furthermore, both TbetaRII-negative and -positive c-myc TGF-alpha HCCs, but not c-myc HCCs, were characterized by decreased levels of the cell cycle inhibitor p27. These results suggest 1) an inverse correlation of decreased p27 expression with the particularly strong expression of TGF-alpha in these lesions, consistent with the capacity of TGF-alpha signaling to post-transcriptionally regulate p27, and 2) the presence of alternative, downstream defects of TGF-beta1 signaling in c-myc/TGF-alpha HCCs that may impair the growth-inhibitory response to TGF-beta1. Thus, the accelerated neoplastic development in c-myc/TGF-alpha mice is associated with an early and frequent occurrence of TbetaRII-negative lesions and with reduced levels of p27 in HCC cells, indicating that disruption of TGF-beta1 responsiveness may play a crucial role in the enhancement of c-myc-induced hepatocarcinogenesis by TGF-alpha.

Citing Articles

CircUCK2(2,3) promotes cancer progression and enhances synergistic cytotoxicity of lenvatinib with EGFR inhibitors via activating CNIH4-TGFα-EGFR signaling.

Wei X, Si A, Zhao S, Fu Y, Li J, Aishanjiang K Cell Mol Biol Lett. 2025; 30(1):15.

PMID: 39885395 PMC: 11781035. DOI: 10.1186/s11658-025-00690-1.


Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.

Ji F, Zhang Z, Zhang Y, Shen S, Cao Q, Zhang L BMC Cancer. 2018; 18(1):460.

PMID: 29690860 PMC: 5926532. DOI: 10.1186/s12885-018-4379-5.


Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma.

Dolezal J, Wang H, Kulkarni S, Jackson L, Lu J, Ranganathan S J Biol Chem. 2017; 292(24):10068-10086.

PMID: 28432125 PMC: 5473214. DOI: 10.1074/jbc.M117.782052.


A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer.

Rojas A, Zhang P, Wang Y, Foo W, Munoz N, Xiao L Neoplasia. 2016; 18(6):371-86.

PMID: 27292026 PMC: 4909706. DOI: 10.1016/j.neo.2016.04.002.


Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer.

Coulouarn C, Factor V, Conner E, Thorgeirsson S Carcinogenesis. 2011; 32(10):1434-40.

PMID: 21771728 PMC: 3179421. DOI: 10.1093/carcin/bgr133.


References
1.
Santoni-Rugiu E, Jensen M, Thorgeirsson S . Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res. 1998; 58(1):123-34. View

2.
Kiss A, Wang N, Xie J, Thorgeirsson S . Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res. 1997; 3(7):1059-66. View

3.
Mulder K, Zhong Q, Choi H, Humphrey L, Brattain M . Inhibitory effects of transforming growth factor beta 1 on mitogenic response, transforming growth factor alpha, and c-myc in quiescent, well-differentiated colon carcinoma cells. Cancer Res. 1990; 50(23):7581-6. View

4.
Murakami H, SANDERSON N, Nagy P, Marino P, Merlino G, Thorgeirsson S . Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 1993; 53(8):1719-23. View

5.
Inagaki M, Moustakas A, Lin H, Lodish H, Carr B . Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A. 1993; 90(11):5359-63. PMC: 46716. DOI: 10.1073/pnas.90.11.5359. View